Detalles de la búsqueda
1.
Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
Mol Ther
; 26(9): 2243-2254, 2018 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30017877
2.
Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
Int J Cancer
; 141(7): 1458-1468, 2017 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28614908
3.
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Mol Ther
; 24(8): 1435-43, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27357626
4.
Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion.
Genes Chromosomes Cancer
; 55(3): 227-36, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26684238
5.
Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial.
Clin Cancer Res
; 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38546220
6.
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
Front Immunol
; 14: 1171083, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37475863
7.
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.
Mol Ther Oncolytics
; 28: 59-73, 2023 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36699617
8.
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Front Immunol
; 14: 1060540, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36817448
9.
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Oncoimmunology
; 12(1): 2241710, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37546696
10.
Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".
Mol Ther
; 24(11): 2033, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27916990
11.
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.
Diseases
; 10(3)2022 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35997357
12.
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.
Oncoimmunology
; 11(1): 2028960, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35083096
13.
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Front Immunol
; 13: 794251, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35355980
14.
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.
Oncoimmunology
; 11(1): 2096572, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35845722
15.
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Cells
; 10(5)2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33922052
16.
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.
Cells
; 10(2)2021 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33513935
17.
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes.
Cancer Gene Ther
; 28(5): 442-454, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32920593
18.
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
Front Immunol
; 12: 674400, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34084172
19.
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
Front Immunol
; 12: 706517, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34367166
20.
Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples.
Hum Gene Ther
; 32(3-4): 192-202, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33050725